Amantadine for Treatment of Symptoms of the Post-Traumatic Confusional State
|ClinicalTrials.gov Identifier: NCT00693121|
Recruitment Status : Unknown
Verified June 2008 by Methodist Rehabilitation Center.
Recruitment status was: Active, not recruiting
First Posted : June 6, 2008
Last Update Posted : June 6, 2008
Patients with traumatic brain injury often experience a period of acute confusion that may include agitation as they recover from their injuries. While this confusion generally resolves with time, patients may pose increased risk of injury to themselves or others during this period. Their behavior may also increase stress for family members and interfere with their ability to benefit from rehabilitation therapies. A number of different medications have been used to treat confusion to decrease agitation, decrease risk of injury, and improve participation in rehabilitation therapies. To this point, there has not been a research or scientific basis for knowing which medication is the best for a specific patient. The overall goal of this study is to conduct a scientific investigation to help determine which medication works best to treat confusion.
Study hypothesis: Amantadine will reduce the severity and number of symptoms of acute confusion after traumatic brain injury.
|Condition or disease||Intervention/treatment||Phase|
|Traumatic Brain Injury Posttraumatic Confusional State Delirium||Drug: Amantadine hydrochloride Drug: Placebo capsule||Phase 4|
Patients with TBI who require inpatient rehabilitation are frequently confused at the time of admission for rehabilitation. Our investigations of confusion conducted as part of the TBIMSM have clarified the nature of confusion in early recovery after TBI. Early confusion (PTCS) has been found to be a complex syndrome characterized by disorientation, cognitive impairment, restlessness, decreased level of daytime arousal, sleep disturbance, fluctuation of symptoms, and psychotic-type symptoms. PTCS complicates early management of patients with TBI, and may contribute to increased risk of injury to patients and hospital staff, increased stress among family members and staff, decreased participation in therapies, increased cost of care, and an increased likelihood of being discharged to psychiatric or long-term care settings. These facts indicate the need for effective management of PTCS. Consensus regarding optimal treatment of the cognitive and behavioral symptoms encountered among patients with PTCS does not exist currently. While many agents have been tried to address such symptoms in TBI, few have been investigated systematically. These circumstances indicate the need for appropriate clinical trials to provide guidance to clinicians for medical treatment of PTCS. In response, the NIDRR-Traumatic Brain Injury Model System of Mississippi proposed a randomized, double-blinded, placebo-controlled, parallel group trial for the pharmacological treatment of PTCS. The agent selected for this clinical trial is amantadine, an NMDA and indirect dopamine agonist. This agent will be compared to placebo on response measures of efficacy and safety.
Study hypothesis: Amantadine will reduce the severity and number of symptoms of PTCS.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||79 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Amantadine Hydrochloride for Treatment of Symptoms of the Post-Traumatic Confusional State Among Neurorehabilitation Admissions With TBI: A Randomized, Double-Blind, Placebo-Controlled Trial|
|Study Start Date :||April 2003|
|Primary Completion Date :||November 2007|
|Estimated Study Completion Date :||June 2008|
Placebo Comparator: Placebo
Identical capsule to amantadine hydrochloride active intervention, administered twice daily x 14 days
Drug: Placebo capsule
capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
Active Comparator: Amantadine
Amantadine hydrochloride 100mg capsule administered twice daily x 14 days
Drug: Amantadine hydrochloride
100mg administered orally twice daily x 14 days
- Confusion Assessment Protocol (number of symptoms) [ Time Frame: 14 days ]
- number of participants withdrawn from study due to fulfillment of "escape criteria" [ Time Frame: 14 days ]
- Time to reach "non-confused" Confusion Assessment Protocol score [ Time Frame: <14 days ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00693121
|United States, Mississippi|
|Methodist Rehabilitation Center|
|Jackson, Mississippi, United States, 39216|
|Principal Investigator:||Stuart A Yablon, M.D.||Brain Injury Program, Methodist Rehabilitation Center|
|Study Director:||Mark Sherer, Ph.D.||Department of Research, Memorial Hermann/TIRR, Houston, TX|
|Study Director:||Risa N Richardson, Ph.D.||Polytrauma Program, James A. Haley Veterans Hospital, Tampa, FL|